The Zemaira Difference

Zemaira raises alpha₁ antitrypsin levels

Zemaira is approved by the FDA for chronic augmentation and maintenance therapy in adults with Alpha-1 and emphysema. CSL Behring is with you every step of the way, offering Alpha-1 patients the support of the CareZ community, a comprehensive suite of services that helps make access to treatment easier.

The benefits of Zemaira

Zemaira provides the range of benefits you expect from an alpha₁ antitrypsin augmentation therapy. Select a benefit below to learn more:

EFFICACY

Proven in clinical trials to raise and maintain therapeutic levels of alpha₁ antitrypsin
- Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available

PURITY

The first highly purified alpha₁ antitrypsin augmentation therapy approved by the FDA
Rigorous purification process helps remove unwanted and unnecessary substances
- Helps reduce the risk of virus transmission
The possibility of transmission of infectious agents cannot be completely eliminated

SAFETY

In clinical trials, the majority of side effects were considered to be mild
- 1% of subjects reported the following mild adverse reactions:
  - Fatigue
  - Injection-site pain
  - Dizziness
  - Headache
  - Tingling
  - Itching

DOSING CONVENIENCE

Low volume of 20 mL requires only 15 minutes to infuse*
Can be stored safely at room temperature
Easy to reconstitute
The recommended dosage of Zemaira is 60 mg/kg body weight once a week

*Based on recommended dosage, as stated in the product package insert, of 60 mg/kg body weight at an infusion rate of 0.08 mL/kg/min.

Talking With Your Doctor

Connect to CareZ™

A community that offers comprehensive support services for patients with Alpha-1

Do I Have Alpha-1?

A simple questionnaire that encourages patients to talk to their doctor about getting tested for Alpha-1

Important Safety Information

Alpha₁-Proteinase Inhibitor (Human), Zemaira^® is indicated for chronic augmentation and maintenance therapy for adults with alpha₁-proteinase inhibitor (A₁-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A₁-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.